Renata Shih, M.D.
Clinical Associate Professor
Department:
MD-CHILD HEALTH RES INSTITUTE
Business Phone:
(352) 294-5757
Business Email:
rshih@peds.ufl.edu
About Renata Shih
Hello my name is Renata L. Shih, MD and I am board-certified in general pediatrics and pediatric cardiology. I received my medical degree from Faculdade Ciencias Medicas Santa Casa de Sao Paulo in Brazil. I completed my pediatric residency at the University of Sao Paulo Children’s Institute and my pediatric cardiology fellowship at the University of Sao Paulo Heart Institute (InCor). I also completed a pediatric residency and pediatric cardiology fellowship at the University of Florida College of Medicine.
I joined the UF Health Congenital Heart Center in 2013 after completing my pediatric cardiology fellowship at University of Florida with a focus in pediatric heart transplant, pulmonary hypertension and heart failure. Before moving to United States, I worked in pediatric intensive care at Santa Catarina Hospital, Sao Camilo Hospital and Cruzeiro do Sul Hospital in Sao Paulo, Brazil.
At UF Health, I am also part of outreach at the pediatric cardiology clinic and participate in a multidisciplinary muscular dystrophy clinic. Additionally, three other authors and myself received The Langley Journal Award for best paper published in Veterinary Anaesthesia and Analagesia for the article, “Determination of cardiac output by ultrasound velocity dilution in normovolemia and hypovolemia in dogs.”
Accomplishments
The Langley Prize for the best paper
2011
·
Vet. Anesthesia and Analgesia Journal
Teaching Profile
Courses Taught
2018
MDC7400 Pediatric Clerkship
2024
BMS6633 The Cv System
Board Certifications
-
Pediatric CardiologyAmerican Board of Pediatrics
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Pediatrics
Subspecialties
- Pediatric Cardiology
- Pediatric Neuromuscular
Areas of Interest
- Amyotrophic lateral sclerosis (ALS)
- Pulmonary hypertension
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-5213-9301
Publications
2024
An Analysis of 186 Transplants for Pediatric or Congenital Heart Disease: Impact of Pretransplant VAD.
The Annals of thoracic surgery.
117(5):1035-1043
[DOI] 10.1016/j.athoracsur.2023.02.063.
[PMID] 37094611.
2024
Impact of prolonged ischemic time on pediatric heart transplantation outcomes: Improved outcomes in the most recent era
The Journal of Heart and Lung Transplantation.
43(7):1142-1152
[DOI] 10.1016/j.healun.2024.03.002.
2024
PROMIS fatigue scores are moderately correlated with heart failure severity in pediatrics
JHLT Open.
6
[DOI] 10.1016/j.jhlto.2024.100144.
2024
Successful implementation of telehealth visits in the paediatric heart failure and heart transplant population.
Cardiology in the young.
34(3):531-534
[DOI] 10.1017/S1047951123001312.
[PMID] 37518866.
2023
An Analysis of 183 Heart Transplants for Pediatric or Congenital Heart Disease-Impact of High Panel Reactive Antibody.
The Annals of thoracic surgery.
115(3):733-741
[DOI] 10.1016/j.athoracsur.2022.10.038.
[PMID] 36370883.
2023
Heart Transplantation in Patients Less Than 18 Years of Age: Comparison of 2 Eras Over 36 Years and 323 Transplants at a Single Institution.
Journal of the American College of Surgeons.
236(4):898-909
[DOI] 10.1097/XCS.0000000000000604.
[PMID] 36794835.
2023
Posterior reversible encephalopathy syndrome (PRES) after pediatric heart transplantation: A multi-institutional cohort
The Journal of Heart and Lung Transplantation.
42(2):218-225
[DOI] 10.1016/j.healun.2022.09.014.
2022
A Comprehensive Approach to the Management of Patients With HLHS and Related Malformations: An Analysis of 83 Patients (2015-2021).
World journal for pediatric & congenital heart surgery.
13(5):664-675
[DOI] 10.1177/21501351221088030.
[PMID] 35511494.
2022
Clinical approach to antibody-mediated rejection from the pediatric heart transplant society.
Pediatric transplantation.
26(8)
[DOI] 10.1111/petr.14398.
[PMID] 36377325.
2022
Clinical approach to vasoplegia in the transplant patient from the Pediatric Heart Transplant Society.
Pediatric transplantation.
26(8)
[DOI] 10.1111/petr.14392.
[PMID] 36377326.
2022
Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION.
Pediatric cardiology.
43(5):977-985
[DOI] 10.1007/s00246-021-02807-7.
[PMID] 35024902.
2022
Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients.
The Journal of thoracic and cardiovascular surgery.
163(4):1462-1473.e12
[DOI] 10.1016/j.jtcvs.2021.02.014.
[PMID] 33745714.
2022
mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study
The Journal of Pediatrics.
243:208-213.e3
[DOI] 10.1016/j.jpeds.2021.12.025.
[PMID] 34952008.
2022
Palliation Plus Ventricular Assist Device Insertion in 15 Neonates and Infants With Functionally Univentricular Circulation.
The Annals of thoracic surgery.
114(4):1412-1418
[DOI] 10.1016/j.athoracsur.2022.02.051.
[PMID] 35304109.
2021
Myocardial recovery following pulsatile biventricular assist device support in infants: Report of 2 cases.
JTCVS techniques.
5:89-92
[DOI] 10.1016/j.xjtc.2020.04.025.
[PMID] 34318118.
2021
Practice variation in the diagnosis of acute rejection among pediatric heart transplant centers: An analysis of the pediatric heart transplant society (PHTS) registry
The Journal of Heart and Lung Transplantation.
40(12):1550-1559
[DOI] 10.1016/j.healun.2021.08.002.
2021
Pulsatile ventricular assist device as a bridge to transplant for the early high-risk single-ventricle physiology.
The Journal of thoracic and cardiovascular surgery.
162(2):405-413.e4
[DOI] 10.1016/j.jtcvs.2020.09.071.
[PMID] 33546851.
2020
Emery‐Dreifuss muscular dystrophy
Muscle & Nerve.
61(4):436-448
[DOI] 10.1002/mus.26782.
[PMID] 31840275.
2020
ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation
The Journal of Heart and Lung Transplantation.
39(4):331-341
[DOI] 10.1016/j.healun.2020.01.1345.
2020
Pediatric donor management to optimize donor heart utilization.
Pediatric transplantation.
24(3)
[DOI] 10.1111/petr.13679.
[PMID] 32198844.
2020
Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
Pediatric transplantation.
24(5)
[DOI] 10.1111/petr.13747.
[PMID] 32497335.
2019
Left Ventricular Aneurysm Following Blunt-Force Trauma in a Child
CASE.
3(1):39-42
[DOI] 10.1016/j.case.2018.08.002.
[PMID] 30828683.
2016
Ventricular Fibrillation-Induced Cardiac Arrest Results in Regional Cardiac Injury Preferentially in Left Anterior Descending Coronary Artery Territory in Piglet Model.
BioMed research international.
2016
[PMID] 27882326.
2013
Determination of Non Invasive Cardiac Output By Electrical Cardiometry Technique in Acute Hemorrhagic Shock Model
Circulation.
128(22, S)
2011
Determination of cardiac output by ultrasound velocity dilution in normovolemia and hypovolemia in dogs.
Veterinary anaesthesia and analgesia.
38(4):279-85
[DOI] 10.1111/j.1467-2995.2011.00604.x.
[PMID] 21627753.
Grants
May 2024
ACTIVE
A PHASE IV OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS AND SAFETY OF RISDIPLAM ADMINISTERED AS AN EARLY INTERVENTION IN PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY AFTER GENE THERAPY
Role: Principal Investigator
Funding: SYNEOS HEALTH
via GENENTECH INC
Dec 2023
ACTIVE
A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy
Role: Principal Investigator
Funding: EDGEWISE THERAPEUTICS
May 2023
ACTIVE
A 2-Part, Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics and Biomarkers in Children with Duchenne Muscular Dystrophy, which includes a Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Part A Followed by Part B, an Open-Label Extension
Role: Principal Investigator
Funding: EDGEWISE THERAPEUTICS
Sep 2021
– Aug 2023
Measuring cardiopulmonary responses to the 6MWT and peak effort exercise in DMD
Role: Co-Investigator
Funding: MUSCULAR DYSTROPHY ASSO
Dec 2020
ACTIVE
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Paral
lel-Group, Event-Driven, Group-Sequential Study with Open-Label Ex
tension Period to Assess the Efficacy and Safety of Selexipag as Add-
On Treatment to Standard of Care in Children Aged =2 to <18 years
with Pulmonary Arterial Hypertension
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Dec 2020
– Oct 2023
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-
On Treatment to Standard of Care in Children Aged =2 to <18 years
with Pulmonary Arterial Hypertension
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Sep 2020
– Sep 2023
A single center, retrospective chart review case report evaluating the safety
and clinical outcomes of eteplirsen (EXONDYS 51) in patients with Duchenne Muscular Dystrophy post heart transplantation
Role: Principal Investigator
Funding: SAREPTA THERAPEUTICS
Jul 2020
ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2020
– Oct 2023
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Oct 2017
ACTIVE
A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with Duchenne muscular dystrophy
Role: Principal Investigator
Funding: MEDPACE
via SOLID BIOSCIENCES INC
May 2017
– Sep 2023
Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Education
Residency – Pediatrics
2010
·
University of Florida
Medical Degree
2000
·
Santa Casa de Sao Paulo
Contact Details
Phones:
- Business:
- (352) 294-5757
Emails:
- Business:
- rshih@peds.ufl.edu
Addresses:
- Business Mailing:
-
PO BOX 100296
RENATA SHIH
GAINESVILLE FL 326100296 - Business Street:
-
2004 MOWRY RD
GAINESVILLE FL 32610